The market is NOT closed tomorrow, just settlement date will be delayed by one day.
ILMN 52 Week Hi this year was $242.37, which means the pre-split high would've been $484.74.
When ILMN stock was $1.21 they had 73 Million shares out, PACB has 77 Million shares out, and a Market Cap of 770 Million as of today, ILMN has a Market Cap of over 25 BILLION as of today, even if PACB only does as good as......1/10th of ILMN , which would put PACB Market Cap at 2.5 BILLION......about 3 1/2 times today's Market Cap/Stock Price.
Do we think PACB can do at least 1/10 th. as good as ILMN ?
Gaps ? Look at the long range chart, all the gaps made going back to the beginning of 2014 have been filed. And anything beyond that is not relevant anymore.
A gap made in 2011 absolutely is not relevant anymore.
How many people that held the stock in 2011 are still in that same position ? I'm not saying there are not still some really long term holders, but not anywhere near the amount to be significant to the stock price.
Past gaps in PACB have no more significance now.
Recent ones have all been filled, and recent ones (a year or less) are the only ones that matter.
This article is from Dec 3rd 2015.
Check out the price targets from ALL the analysts following ONDK.
Several other analysts have also recently issued reports on ONDK. FBR & Co. restated a buy rating and issued a $14.00 price objective on shares of On Deck Capital in a report on Wednesday. Keefe, Bruyette & Woods upgraded shares of On Deck Capital from a market perform rating to an outperform rating and set a $14.50 target price for the company in a report on Wednesday. Zacks Investment Research upgraded shares of On Deck Capital from a hold rating to a buy rating and set a $11.00 price objective for the company in a report on Wednesday, November 25th. Canaccord Genuity reaffirmed a buy rating and issued a $18.00 target price on shares of On Deck Capital in a research report on Wednesday, November 4th. Finally, BTIG Research reissued a buy rating and set a $18.00 price objective on shares of On Deck Capital in a research report on Wednesday, November 4th. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating and eleven have issued a buy rating to the stock. The stock has an average rating of Buy and an average target price of $15.83.
Once this morning, and this noon. Probably will be mentioned two more times today. Check out the video on the Yahoo front page, it's also on the ILMN Yahoo front page.
Long-Read Sequencing in the Age of Genomic Medicine
By Aaron Krol
December 16, 2015 | This September, Pacific Biosciences announced the creation of the Sequel, a DNA sequencer half the cost and seven times as powerful as its previous RS II instrument. PacBio, with its unique long-read sequencing technology, had already secured a place in high-end research labs, producing finished, highly accurate genomes and helping to explore the genetic “dark matter” that other next-generation sequencing (NGS) instruments miss. Now, in partnership with Roche Diagnostics, PacBio is repositioning itself as a company that can serve hospitals as well.
“Pseudogenes, large structural variants, validation, repeat disorders, polymorphic regions of the genome―all those are categories where you practically need PacBio,” says Bobby Sebra, Director of Technology Development at the Icahn School of Medicine at Mount Sinai. “Those are gaps in the system right now for short-read NGS.”
Mount Sinai’s genetic testing lab owns three RS II sequencers, running almost around the clock, and was the first lab to announce it had bought a Sequel just weeks after the new instruments were launched. (It arrived earlier this month and has been successfully tested.) Sebra’s group uses these sequencers to read parts of the genome that, thanks to their structural complexity, can only be assembled from long, continuous DNA reads
Icahn's Billionaire buddies will get in on the act, Gates, Buffet,......Trump......just to name a few.
Myself, I always listen to the stock, the company doesn't really have to give daily, weekly, or monthly sales figures, or constant updates. The stock is saying things are going positive.
All of them. They have a very big decision to make now, it can get worse......a lot worse.
They are going to have a difficult time trying to find shares to cover with....without bidding the price up from here.
This is a short squeeze in the making.......hang in there longs, don't give them your shares to cover with.
So today PACB is at an almost 5 year high. Which means ALL the current shorts shorted at.........LOWER prices than today. That spells BIG trouble for them.
For you longs that sell your stock now, you are just gifting them shares to cover with, at Schwab PACB is a HTB stock.......Hard To Borrow.
If they can't find stock to cover at this price, it just means............they are going to have to bid up the price to find shares to cover their short position with.
Do NOT sell your PACB !